BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Cemiplimab: trial readouts and FDA decisions

1 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 8 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Regeneron Pharmaceuticals, Vyriad, Inc., OncoResponse, Inc., EMD Serono Research & Development Institute, Inc., Sensei Biotherapeutics, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01-15 est.P3Regeneron Pharmaceuticals REGNNCT05608291 A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it HasMelanomaactive not recruiting1564

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-13 est.P1/P2Regeneron Pharmaceuticals REGNNCT04626635 A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersAdvanced Solid Tumorsactive not recruiting548
2026-11-02 est.P2Regeneron Pharmaceuticals REGNNCT06190951 A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaMelanomaactive not recruiting151
2026-10 est.P2Vyriad, Inc.NCT04291105 Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer PatientsMelanoma; Head and Neck Squamous Cell Carcinoma; Colo-rectal Canceractive not recruiting87
2026-08-24 est.P2Regeneron Pharmaceuticals REGNNCT06161441 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in AResectable Non-small Cell Lung Canceractive not recruiting195
2026-08-01 est.P1/P2OncoResponse, Inc.NCT06090266 A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer AgentsCancer; Tumor, Solid; Malignant Neoplasm; Metastatic Cancer; Advanced Solid Tumor; Cutaneous Melanomrecruiting168
2026-07-15P1/P2EMD Serono Research & Development Institute, Inc.NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)Non-Small Cell Lung Cancercompleted61
2026-06-08 est.P2Regeneron Pharmaceuticals REGNNCT06384820 Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous SquCutaneous Squamous Cell Carcinomawithdrawn
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.